{"id":"W2888094806","doi":"10.1016/j.ejca.2018.07.007","title":"A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Halozyme; Novocure; Celgene; Pfizer; Oncolytics Biotech; Eli Lilly and Company","keywords":"Gemcitabine; Capecitabine; Medicine; Tolerability; Cisplatin; Internal medicine; Oncology; Paclitaxel; Clinical endpoint; Chemotherapy; Phases of clinical research; Adenocarcinoma; Deoxycytidine; Surgery; Gastroenterology; Clinical trial; Cancer; Adverse effect","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00211268,0.002364002,0.003877517,0.0007090464,0.0005517069,0.001712992,0.001439824,0.00224073,0.01220595],"category_scores_gemma":[0.002493813,0.001395384,0.00220366,0.0006867579,0.00203274,0.002235595,0.0008249741,0.004844099,0.001828376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001257882,"about_ca_system_score_gemma":0.001702891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001623248,"about_ca_topic_score_gemma":0.003544283,"domain_scores_codex":[0.9991438,0.0004714085,0.00005080478,0.0001634574,0.00003871524,0.0001317383],"domain_scores_gemma":[0.998804,0.0003771835,0.0001582153,0.0001395319,0.00005034664,0.0004707213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.985235,0.004942398,0.0002190584,0.000239296,0.0003161072,0.00003136238,0.00005507005,0.0003823593,0.001809357,0.00006992494,0.0003484309,0.006351749],"study_design_scores_gemma":[0.9622014,0.03643682,0.0004474365,0.0000119488,0.0001495991,0.00001699658,0.00001791545,0.0001598444,0.0001678028,0.00009441909,0.0002867492,0.000009158418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891613,0.001889651,0.0005487984,0.000867454,0.00092576,0.003264286,0.0009052169,0.0001145859,0.002322954],"genre_scores_gemma":[0.9820333,0.002108239,0.002017356,0.001455678,0.0006295987,0.004356408,0.001906218,0.00007284132,0.005420469],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01220595,"threshold_uncertainty_score":0.040833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03735224206187664,"score_gpt":0.3747354699927424,"score_spread":0.3373832279308657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}